The MMRV vaccine will become part of the routine childhood immunisation schedule in the UK from 1 January 2026.
Similar Posts
MHRA begins recruitment for new digital roles at Leeds hub to drive innovation and smarter regulation
New jobs to strengthen innovation, safety and smarter regulation across the UK health and life sciences sector.
Medicines regulator approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only
The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.
Medicines: apply for a parallel import licence
How to get a parallel import licence for your medicine in the UK, including pharmacovigilance requirements and submitting your application.
Corporate report: MHRA: policy for handling corporate conflicts of interest
Information about how we handle potential corporate conflicts of interest (COI) between different parts of the Agency.
Promotional material: Vaccine safety – patient factsheet
Patient factsheet to provide information on vaccines and vaccine safety.
Looking to our future: reflections on the strategic choices ahead for the MHRA
As part of developing its new five-year strategy, the MHRA is publishing a series of blogs on the challenges and opportunities ahead. In the first instalment, Chief Executive Lawrence Tallon reflects on the changing healthcare landscape, the regulator’s role, and the priorities shaping the agency’s future direction.